当前位置:首页 - 行情中心 - 诺诚健华-U(688428) - 财务分析 - 利润表

诺诚健华-U

(688428)

  

流通市值:23.41亿  总市值:160.75亿
流通股本:2.57亿   总股本:17.63亿

利润表

报告期2023-12-312023-09-302023-06-302023-03-31
公司类型通用通用通用通用
一、营业总收入738,537,047.65537,361,649.4377,549,019.52189,387,628.4
营业收入738,537,047.65537,361,649.4377,549,019.52189,387,628.4
二、营业总成本1,377,500,498.71,088,452,691.35821,426,216.01207,586,324.78
营业成本128,435,146.12100,879,190.976,072,433.0742,897,028.9
税金及附加9,704,437.236,713,226.464,225,772.622,273,281.01
销售费用366,891,163.84267,298,034.29191,208,076.485,962,493.69
管理费用184,122,329.22127,943,846.0683,184,462.2336,912,035.95
研发费用757,253,137.36549,716,988.65361,193,556.11140,950,687.03
财务费用-68,905,715.0735,901,404.99105,541,915.58-101,409,201.8
其中:利息费用35,211,746.7130,510,275.3720,441,627.1610,360,573.2
其中:利息收入192,333,014.71143,640,174.1393,770,842.2546,138,411.62
加:公允价值变动收益-53,962,753.45-23,480,706.51-15,417,163.14-6,459,371.68
加:投资收益5,571,778.88-3,526,776.07-2,087,403.09-709,134.68
信用减值损失(新)-268,084.4832,389.0832,090.7-
其他收益36,468,381.5729,211,621.3424,230,369.3311,137,224.44
营业利润平衡项目0000
四、营业利润-651,154,128.53-548,854,514.11-437,119,302.69-14,229,978.3
加:营业外收入11,782,24911,475,062.568,443,196.04612.9
减:营业外支出4,833,746.921,907,814.33506,675.37-
利润总额平衡项目0000
五、利润总额-644,205,626.45-539,287,265.88-429,182,782.02-14,229,365.4
减:所得税费用1,425,960.95---
六、净利润-645,631,587.4-539,287,265.88-429,182,782.02-14,229,365.4
持续经营净利润-645,631,587.4-539,287,265.88-429,182,782.02-14,229,365.4
归属于母公司股东的净利润-631,262,907.71-531,165,508.57-422,209,548.49-12,406,466.71
少数股东损益-14,368,679.69-8,121,757.31-6,973,233.53-1,822,898.69
(一)基本每股收益-0.37-0.31-0.25-0.01
(二)稀释每股收益-0.37-0.31-0.25-0.01
八、其他综合收益113,543,810.79201,686,015.77233,690,430.14-86,273,096.48
归属于母公司股东的其他综合收益113,543,810.79201,686,015.77233,690,430.14-86,273,096.48
九、综合收益总额-532,087,776.61-337,601,250.11-195,492,351.88-100,502,461.88
归属于母公司股东的综合收益总额-517,719,096.92-329,479,492.8-188,519,118.35-98,679,563.19
归属于少数股东的综合收益总额-14,368,679.69-8,121,757.31-6,973,233.53-1,822,898.69
公告日期2024-03-292023-11-142023-08-302023-05-10
审计意见(境内)标准无保留意见
TOP↑